HSIC250117P95000
- 0.00
- 0.000.00%
Henry Schein Newsroom
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX), Henry Schein (HSIC) and Geron (GERN)
Henry Schein Analyst Ratings
Mizuho Initiates Coverage On Henry Schein With Neutral Rating, Announces Price Target of $75
Hold Rating Maintained for Henry Schein Amid Market Challenges and Activist Investor Influence
Piper Sandler Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $83
Piper Sandler Keeps Their Buy Rating on Henry Schein (HSIC)
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $74 to $83
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
Henry Schein Price Target Maintained With a $82.00/Share by Barrington Research
Henry Schein Is Maintained at Outperform by Barrington Research
Henry Schein Analyst Ratings
Henry Schein: Buy Rating Affirmed Amid Strong Profitability and Strategic Cost Management
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $55 to $83
Henry Schein (HSIC) Gets a Buy From Piper Sandler
Henry Schein's Sell Rating: Internal Sales Weakness and Valuation Concerns Amidst Cybersecurity and Market Challenges
BofA Securities Maintains Henry Schein(HSIC.US) With Sell Rating
Bank of America Securities Sticks to Their Sell Rating for Henry Schein (HSIC)
CFRA Initiates Henry Schein(HSIC.US) With Sell Rating, Announces Target Price $67
Henry Schein Is Maintained at In-Line by Evercore ISI Group
Henry Schein Analyst Ratings